mHSPC COE

Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg

Details
In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....

mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022: Treatment...

The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz

Details
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam

Details
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

Details
Alicia Morgans and Karim Fizazi discuss quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study and which patient populations benefit most from this data. Dr Fizazi also details the P6 platform. P6 is for all patients with metastatic castration-sensitive disease. There are different phase three trials called P6. Drs Morgans and Fizazi discuss the P6 vulnerable...

The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore

Details
Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...

APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy. Biographies: Evan Yu, MD , Professor, Department of Medici...

Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Gert Attard presents on whether we need more granularity in mHSPC, and whether biology can help with treatment decisions. Biographies: Gert Attard, MD, PhD, FRCP, John Black Charitable Foundation Endowed Chair in Urological Cancer Research, University College London Cancer Institute, London, UK Related Content: APCCC...

When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Treat like Low-Volume APCCC 2022 Presentation - Karim Fizazi

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Karim Fizazi presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like low volume patients. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University of...

A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore

Details
Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT. Drs. Shore and Morgans speak about the clinical implications of this approval from a urologist's perspective. The approval was based on the overall survival data Matthew Smith presented at ASCO GU 2022 and the 32% reduction in mortal...
email news signup